Bristol Myers Squibb today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for…
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental…
Roche announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for treating diabetic macular edema (DME) and diabetic retinopathy (DR),…
Roche announced new, four-year data from the RHONE-X extension study today. The study met all primary endpoints, demonstrating that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema…
Roche announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist for treating type…
Zura Bio, a clinical-stage immunology company specializing in dual-pathway antibodies for autoimmune and inflammatory diseases, has announced the commencement of an exchange offer (the “Offer”) and consent solicitation (the “Consent…
Revolution Medicines, a clinical-stage oncology company dedicated to targeting RAS-addicted cancers, has announced the publication of a peer-reviewed research paper in Cancer Discovery. The paper showcases the efficacy of their…
Global pharmaceutical leader Lupin Limited (Lupin) has announced the approval of its Abbreviated New Drug Application by the United States Food and Drug Administration (U.S. FDA) for Topiramate Extended-Release Capsules.…
Global pharmaceutical leader Lupin Limited announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility…
The World Health Organization has released “The Role of Parliaments and Parliamentarians in Strengthening Health Security Preparedness,” an online training course designed to equip parliamentarians with the knowledge and tools…
In April, at the United Nations Headquarters in New York, governments reaffirmed their commitment to the Programme of Action from the 1994 International Conference on Population and Development (ICPD). The…
Today, AbbVie announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new indication for upadacitinib (RINVOQ®; 15…